Send me real-time posts from this site at my email

Stephens begins coverage of Akoya Biosciences (NASDAQ:AKYA).

Originally published on Best Stocks

Category: best stocks to buy now

On Wednesday, Stephens began covering Akoya Biosciences by disseminating a research note to the investment community (NASDAQ: AKYA). The rating given to the stock by the investment company was “overweight.”

Deposit $100 and get a $110 to trade stocks
>>>>>>>>>>Open Account

AKA has been the topic of research articles written by various stock research analysts throughout the past few years. On Wednesday, August 17 August 17, Piper Sandler published a research note in which they increased their price target for Akoya Biosciences from $14.00 to $17.00 and gave the stock an “overweight” rating. Piper Sandler’s research note can be found here. The research note that Piper Sandler has written can be seen here. A research report published by TheStreet on Tuesday, September 13, September 13, gave Akoya Biosciences a rating of “d,” downgraded from “c-,” which was the previous rating. In a research report made available to the public on Monday, August 15, August 15, BTIG Research stated that they had increased their price target for Akoya Biosciences to twenty dollars. There have been four people who are experts in equity research who have suggested buying the stock. They are all interested in investing. Bloomberg’s data shows that the most common recommendation for Akoya Biosciences stock is “Buy,” and the average price target is $18.67.
Wednesday’s trading activity resulted in a decrease of $0.02 in the price of a share of Akoya Biosciences, which ultimately settled at $12.67 for the day. The volume of shares traded by the company was significantly lower than its average of 111,152 shares, coming in at 66,184 shares. Over the previous 52 weeks, the highest and lowest price that Akoya Biosciences reached was $16.57. The company’s simple moving average for the previous 200 days is $11.76, while the simple moving average for the most recent 50 days is $12.96. The company’s market capitalization is reported to be $476.27 million, while its price-to-earnings ratio stands at -7.50, and its beta value is 0.66. The debt-to-equity ratio is 0.48, the current ratio is 3.55, and the quick ratio is 3.16. All of these numbers are very close to one another.

On August 8 August 8, the most recent earnings report for Akoya Biosciences was released. Akoya Biosciences shares are traded on the NASDAQ under the ticker symbol AKYA. The company announced earnings of $0.47 per share for the quarter, which fell short of the consensus estimate of $0.34 among market experts, which was $0.13. The company also reported a net loss of $0.47 million for the quarter. In addition, theaddition, bothnet margin and equity return for Akoya Biosciences were in the red. The net margin was -98.08%, and the return on equity for the company was-55.41%. The final tally for the company’s revenue for the quarter was $17.89 million, which was substantially higher than the estimate provided by the market, which was $16.93 million. The company generated $0.20 per share during the same year. According to estimates provided by sell-side analysts, the earnings of Akoya Biosciences for the current fiscal year are expected to amount to a loss of 1.65 cents per share, according to estimates provided by sell-side analysts.

On top of that, Brian Mckelligon, Chief Executive Officer of Akoya Biosciences, sold 5,000 of the company’s shares of stock on September 7. Throughout the day, a total of shares worth $64,150.00 were sold at an average price of $12.83 per share, making the total value of shares sold for the day $64,150.00. After the deal’s completion, the Chief Executive Officer will have 80,000 shares of the company, each of which has a value of $1,026,400. You can read the transaction’s legal documentation submitted to the Securities and Exchange Commission by clicking on the link provided here to access it. On Friday, September 9 September 9, it was reported that Director Garry, Ph.D. Nolan sold 22,191 shares of the company’s stock, consistent with what was reported in other news regarding Akoya Biosciences. The price of each share was determined to be $13.31 on average after the sale of the shares, which resulted in total revenue of $295,362.21. Following the completion of the sale, the director will have a total of 632,893 shares in the company. At the moment, these shares have a value of $8,423,805.83. You can read the transaction’s legal documentation submitted to the Securities and Exchange Commission by clicking on the link provided here to access it. In addition, Brian Mckelligon, who serves as the Chief Executive Officer of Akoya Biosciences, sold 5,000 of the company’s shares of stock on September 7. Throughout the day, a total of shares worth $64,150.00 were sold at an average price of $12.83 per share, making the total value of shares sold for the day $64,150.00. Following the transaction’s completion, the company’s chief executive officer now directly owns 80,000 shares of the company’s stock, the total value of which is approximately $1,026,400. The disclosure regarding the sale can be found at this location. Insiders of a company have sold 37,296 shares of company stock with a combined value of $493,571 over the past three months. Employees of the company own 9.20% of the total shares in the company, making them significant shareholders.

In recent times, there has been significant market activity from various institutional investors buying and selling shares of AKYA. American International Group Inc. increased its holdings of Akoya Biosciences stock by 10.8 percent in the second quarter compared to the previous quarter. American International Group Inc. now has 7,381 shares in the company after purchasing an additional 718 shares during the most recent quarter. The value of American International Group Inc.’s stock in the company is currently $95,000. In addition, a financial contribution of $26,000 was made to Akoya Biosciences by Nisa Investment Advisors LLC during the second quarter of 2018. JPMorgan Chase & Co. increased the amount of Akoya Biosciences stock held by 34.00% during the year’s second quarter. After purchasing an additional 2,138 shares during the most recent quarter, JPMorgan Chase & Co. now owns 8,431 shares, valued at $108,000. These shares were acquired during the most recent quarter. During the first three months of 2018, Charles Schwab Investment Management Inc. increased the amount of Akoya Biosciences stock owned by a percentage equal to 12.0%. After making an additional purchase of 7,243 shares during the preceding quarter, Charles Schwab Investment Management Inc. now owns 67,401 shares of the company, which have a combined value of $741,000 after taking into account the company’s current share price. Last but certainly not least, Qube Research & Technologies Ltd. increased the percentage of Akoya Biosciences stock owned by 44.4% during the year’s first three months. As a result of the acquisition of an additional 8,652 shares during the most recent quarter, Qube Research & Technologies Ltd now holds a total of 28,153 shares of the company’s stock. The value of these shares brings the company’s total market capitalization to $309,000. Hedge funds and other institutional investors have a combined ownership stake in the company equal to 34.54% of its total shares.

To revolutionize clinical research and discovery worldwide, including in North America, Asia Pacific, Europe, the Middle East, and Africa, Akoya Biosciences, Inc., a company specializing in the technology of the life sciences, provides solutions in the field of spatial biology. These solutions can be found on their website. Using the PhenoCycler instrument, a small bench-top fluidics system that integrates with a companion microscope to automate image acquisition, researchers can visualize, analyze, quantify, and phenotype cells in situ and in fresh frozen or FFPE tissue sections, and tissue microarrays. This is possible in all of these different types of tissue sections. This workflow is not only high-throughput but also fully automated.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue